Jun. 13 at 9:32 PM
$CTXR It would be better to be long than short this stock over the next
12 months. This board is all old-season veterans in the bio field who have been with CTXR for years. They all own stock and a shit load of options that are mostly out of the money at this time. They have given us a bread crumb when they all renewed their contracts for just 1 year. The financing they gave CTOR was hinge to conversioning the money into CTOR stock on a moment's notice at .90. This being that in a major buyout, they can take advantage of the buyout price. As Jefferies is in the Data room, pushing the sale or licensing deal for Lymphir as the first shoe to drop. Once that is completed, the real gem of CTXR, which is one step away from FDA approval, can be sold or built out with the Lymphir money. Halo Lido is the icing on the cake. A big pharma company will buy both or sold separately, where the board and share
holders will ride off into the sunset with a big check.Gemini, the board and their history.
